AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.
The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus
The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies
The application sought approval for Ebvallo as monotherapy in adult and paediatric patients aged two years and above with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have
Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
